Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across biomedical AI, cancer, cardiovascular diseases, inflammation, immunity, age-related, rare and infectious diseases.

          Learn more

        • Biomedical AI
        • Cancer Innovations
        • Cardiovascular Research
        • Healthy Ageing
        • Infection & Immunity
        • Inflammation
        • Rare Diseases & Gene Therapy
        • Laboratories
        • Diseases
        • Expertises
        • Breakthroughs
        • Technologies
          • Clinical Translation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your Will
        • Donate in Memory
        • Community and research
  • Careers & students
        • Careers & Students

          Postdoctoral and postgraduate students can work alongside world-leading medical researchers within state-of-the-art research facilities.

        • Career Opportunities
        • Student Opportunities
  • Health hub
        • Health hub

          A range of practical information to assist in the possible preventions to disease through evidence-based research on how the body works.

          Learn more

        • Inflammation
        • The Good Gut Anti-Inflammatory Diet
          • Healthy Recipes
        • Ageing
        • Exercise Snack Program
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events

        • News
        • Events
        • Media Hub
          • Statements
        • Real stories
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Our researchers
          • Animals in research
        • Contact
  • Donate
    Centenary Institute > News > New funding to advance gene therapies

New funding to advance gene therapies

Date time 24 May, 2023
News Type News type Media release
LtoR – Professor John Rasko AO, Dr Bijay Dhungel and Dr Chuck Bailey
Researchers at the Centenary Institute and the Sydney Local Health District (SLHD) have been awarded $500,000 from CUREator, Australia’s national biotech incubator, to develop new technology to improve the safe and effective delivery of gene therapy.

The gene therapy technology will be developed by the researchers in a new start-up company called AAVec Bio, that will be dedicated to advancing adeno-associated virus (AAV) technology. This bioengineered virus technology, that serves as a vehicle to transport healthy genes to cells, will be used to potentially cure a diverse group of genetic diseases.

Led by Professor John Rasko AO, from the Centenary Institute and the Royal Prince Alfred Hospital (SLHD), the research team aims to develop a novel AAV technology that will be more effective at delivering therapeutic genes to the correct cells in the body.

The researchers say the hope is to overcome some current limitations of AAV-based gene therapy, including the need for high AAV doses to achieve therapeutic effects, dose-related toxicities and high manufacturing costs.

“The success of gene therapy depends on how effectively the therapeutic payload is delivered to target cells in the body,” said Professor Rasko.

“Our novel platform could greatly improve human gene therapies, leading to more effective treatments for those suffering with unmet medical needs. It would also mean substantially reduced dosage levels are required, with less toxicities and side effects, leading to improved outcomes for patients.”

Another exciting aspect of the work relates to the current high cost of gene-based drugs as the researchers anticipate that their new AAV approach could significantly decrease manufacturing costs by five- or even ten-fold, due to the reduced amount of therapeutic material required.

“This cost saving could potentially transform the gene therapy market by making these treatments far more accessible and affordable to patients,” said Professor Rasko.

The researchers intend to first demonstrate the utility of their new technology for gene therapy in Pompe disease, a rare genetic disorder that leads to progressive muscle weakness and damage to the heart. Ultimately the technology could improve gene therapies for thousands of different rare diseases that affect two million Australians.

“Pompe disease affects the body’s ability to breakdown glycogen, which accumulates in tissues like muscle and causes damage. It affects about 1 in 40,000 people globally,” said Dr Chuck Bailey, senior scientist at the Centenary Institute and AAVec Bio.

Dr Bijay Dhungel, scientist at the Centenary Institute and AAVec Bio stated, “By using gene therapy to replace the defective gene, we have the potential to achieve a long-lasting curative outcome for Pompe disease, in addition to demonstrating the proof-of-principle of our AAV technology and the effectiveness of our new approach.”

[ENDS]

Laboratories

  • Bailey

People

  • Dr Charles Bailey

    Head, Centre for Rare Diseases & Gene Therapy

Media enquires

For all media and interview enquiries, please contact Tony Crawshaw

Phone number Phone Number +61 402 770 403

Email Email t.crawshaw@centenary.org.au

Media Release

New funding to advance gene therapies

Download

Recent Stories

  • New COVID-19 vaccine candidate shows strong protection against multiple variants

    A promising new COVID-19 vaccine candidate developed by researchers at the Centenary Institute and the University of Sydney has shown strong potential to protect against both current and emerging coronavirus variants. By targeting features shared by a range of coronaviruses, the vaccine is designed to offer broader and longer-lasting protection as the virus continues to evolve.
    News Type: Media release
    Date 18 Jul 2025
  • New route into cells could make gene therapies safer

    Scientists from the Centenary Institute and the University of Sydney have made a landmark discovery that could lead to safer and more effective gene therapies for a range of serious genetic disorders including Duchenne muscular dystrophy, Pompe disease and haemophilia.
    News Type: Media release
    Date 15 Jul 2025
  • Centenary researchers awarded TIA Pipeline Accelerator Grants

    Two researchers from the Centenary Institute have secured competitive Pipeline Accelerator Grants from Therapeutic Innovation Australia (TIA), supporting the development of promising medical innovations.
    News Type: Research News
    Date 07 Jul 2025
  • Research grant to tackle Alzheimer’s disease

    A research team led by Professor Jennifer Gamble from the Centenary Institute’s Centre for Healthy Ageing has been awarded a prestigious Catalyst Partnership Grant from the Heart Foundation.
    News Type: Research News
    Date 03 Jul 2025

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About
  • Governance
  • Corporate information

Research

  • Our researchers
  • News
  • Media hub

Careers & studies

  • Career opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Contact Privacy

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram